Jessica L. Kennedy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jessica L. Kennedy has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Anne Walker
Department of Allergy, Immunology and Respiratory Medicine Alfred Hospital Melbourne Victoria Australia
1 shared publicationCatherine Martin
Public Health and Preventative Medicine Monash University Melbourne Victoria Australia
1 shared publicationCatherine Smith
Public Health and Preventative Medicine Monash University Melbourne Victoria Australia
1 shared publication- Charles A. Czeisler
Division of Sleep and Circadian Medicine, Department of Medicine, Mass General Brigham, Boston, USA
1 shared publication Claire M. Ellender
Department of Allergy, Immunology and Respiratory Medicine Alfred Hospital Melbourne Victoria Australia
1 shared publication- Elise R. Facer-Childs
Monash University, Clayton, Australia
1 shared publication
Latest Publications
- Open Access
- 3 June 2021
- Published by Wiley in Respirology
- Vol. 26 (7) , 707-712
Delay or avoidance of routine, urgent and emergency medical care due to concerns about COVID‐19 in a region with low COVID‐19 prevalence: Victoria, Australia
- 3 June 2021
- Published by Wiley in Respirology
- Vol. 26 (7) , 707-712
Open AccessDelay or avoidance of routine, urgent and emergency medical care due to concerns about COVID‐19 in a region with low COVID‐19 prevalence: Victoria, Australia
- 3 March 2021
- Published by Wiley in Internal Medicine Journal
- Vol. 52 (6) , 995-1001
Outcomes of non‐cystic fibrosis‐related bronchiectasis post‐lung transplantation
Background: Lung transplantation is a recognised treatment for end‐stage lung disease due to bronchiectasis. Non‐cystic fibrosis (CF) bronchiectasis and CF are often combined into one cohort; however, outcomes for non‐CF bronchiectasis patients vary between centres, and in comparison with those for CF.Aims: To compare lung transplantation mortality and morbidity of bronchiectasis (non‐CF) patients with those with CF and other indications.Methods: Retrospective analysis of patients undergoing lung transplantation between 1 January 2008 and 31 December 2013. Time to and cause of lung allograft loss was censored on 1 April 2018. A case‐note review was conducted on a subgroup of 78 patients, to analyse hospital admissions as a marker of morbidity.Results: A total of 341 patients underwent lung transplantation; 22 (6%) had bronchiectasis compared with 69 (20%) with CF. The 5‐year survival for the bronchiectasis group was 32%, compared with CF (69%), obstructive lung disease (OLD) (64%), pulmonary hypertension (62%) and ILD (55%) (P = 0.008). Lung allograft loss due to chronic lung allograft dysfunction with predominant infection was significantly higher in the bronchiectasis group at 2 years. The rate of acute admissions was 2.24 higher in the bronchiectasis group when compared with OLD (P = 0.01). Patients with bronchiectasis spent 45.81 days in hospital per person year after transplantation compared with 18.21 days for CF.Conclusions: Bronchiectasis patients in the present study had a lower 5‐year survival and poorer outcomes in comparison with other indications including CF. Bronchiectasis should be considered a separate entity to CF in survival analysis.
- 3 March 2021
- Published by Wiley in Internal Medicine Journal
- Vol. 52 (6) , 995-1001
Outcomes of non‐cystic fibrosis‐related bronchiectasis post‐lung transplantation
Background: Lung transplantation is a recognised treatment for end‐stage lung disease due to bronchiectasis. Non‐cystic fibrosis (CF) bronchiectasis and CF are often combined into one cohort; however, outcomes for non‐CF bronchiectasis patients vary between centres, and in comparison with those for CF.Aims: To compare lung transplantation mortality and morbidity of bronchiectasis (non‐CF) patients with those with CF and other indications.Methods: Retrospective analysis of patients undergoing lung transplantation between 1 January 2008 and 31 December 2013. Time to and cause of lung allograft loss was censored on 1 April 2018. A case‐note review was conducted on a subgroup of 78 patients, to analyse hospital admissions as a marker of morbidity.Results: A total of 341 patients underwent lung transplantation; 22 (6%) had bronchiectasis compared with 69 (20%) with CF. The 5‐year survival for the bronchiectasis group was 32%, compared with CF (69%), obstructive lung disease (OLD) (64%), pulmonary hypertension (62%) and ILD (55%) (P = 0.008). Lung allograft loss due to chronic lung allograft dysfunction with predominant infection was significantly higher in the bronchiectasis group at 2 years. The rate of acute admissions was 2.24 higher in the bronchiectasis group when compared with OLD (P = 0.01). Patients with bronchiectasis spent 45.81 days in hospital per person year after transplantation compared with 18.21 days for CF.Conclusions: Bronchiectasis patients in the present study had a lower 5‐year survival and poorer outcomes in comparison with other indications including CF. Bronchiectasis should be considered a separate entity to CF in survival analysis.